Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | IL1B | P01584 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19784980 | 0.86 | SMN1; SMN2 (0.40) | SMN1; SMN2USP2ATMRECQLIL1B | |
| SCHEMBL4955652 | 0.83 | DPP4 (0.44) | SMN1; SMN2ATMALDH1A1KDM1A | |
| SCHEMBL8290278 | 0.83 | DPP4 (0.44) | SMN1; SMN2ATMALDH1A1KDM1A | |
| SCHEMBL8272551 | 0.82 | MEN1 (0.34) | ALDH1A1 | |
| SCHEMBL1598306 | 0.81 | SMN1; SMN2 (0.45) | SMN1; SMN2USP2ATMRECQLIL1B | |
| SCHEMBL553866 | 0.79 | SMN1; SMN2 (0.43) | SMN1; SMN2USP2ATMRECQLIL1B | |
| SCHEMBL553865 | 0.79 | SMN1; SMN2 (0.43) | SMN1; SMN2USP2ATMRECQLIL1B | |
| SCHEMBL307099 | 0.77 | PDK1 (0.49) | SMN1; SMN2USP2ATMRECQLIL1B | |
| SCHEMBL20371626 | 0.77 | USP2 (0.49) | SMN1; SMN2USP2ATMRECQLIL1B | |
| SCHEMBL14417217 | 0.77 | USP2 (0.49) | SMN1; SMN2USP2ATMRECQLIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| CN-101005835-A | 1-[(3r)-amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2r)-carboxylic acid-benzyl amine derivatives and related compounds as dipeptidyl-peptidase iv (dpp-iv) inhibitors for the treatment of type 2 diab | SANTHERA PHARMACEUTICALS CH (CH) | 2007-07-25 | — | — | CN | disclosed |
| EP-1791536-A1 | 1-[(3R)-AMINO-4-(2-FLUORO-PHENYL)-BUTYL]-PYRROLIDINE-(2R)-CARBOXYLIC ACID-BENZYL AMINE DERIVATIVES AND RELATED COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV (DPP-IV) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| WO-2005120494-A1 | 1-`(3R)-AMINO-4-(2-FLUORO-PHENYL)-BUTYL !-PYRROLIDINE-(2R)-CARBOXILIC ACID-BENZYL AMINE DERIVATIVES AND RELATED COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV (DPP-IV) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP7 | SMN1; SMN2 4552/4885USP2 1466/4885ATM 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.